Trial from ClinicalTrials.gov

For full trial details, please see the original record at



Trial ID
NCT02273375
Ethics application status
Date submitted
22/10/2014
Date registered
22/10/2014
Date last updated
10/10/2017

Titles & IDs
Public title
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
Scientific title
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer
Secondary ID [1] 0 0
IFCT1401
Secondary ID [2] 0 0
BR31
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-Small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: drugs - MEDI4736
Treatment: drugs - Placebo

Experimental: MEDI4736 - MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier.

Placebo Comparator: Placebo - PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier


Treatment: drugs: MEDI4736


Treatment: drugs: Placebo


Intervention code [1] 0 0
Treatment: drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Compare Disease free survival (DFS) for patients with NSCLC that is PD-L1 positive
Timepoint [1] 0 0
5.5 years
Secondary outcome [1] 0 0
Compare Disease Free Survival in all randomized patients
Timepoint [1] 0 0
7 years
Secondary outcome [2] 0 0
Compare overall survival (OS) for patients with NSCLC that is PD-L1 positive
Timepoint [2] 0 0
5.5 years
Secondary outcome [3] 0 0
Compare overall survival for all randomized patients
Timepoint [3] 0 0
7 years
Secondary outcome [4] 0 0
Compare Lung cancer specific survival for patients with NSCLC that is PD-L1 positive and all randomized patients
Timepoint [4] 0 0
7 years
Secondary outcome [5] 0 0
Evaluate the nature, severity and frequency of adverse effects and tolerability of MEDI4736 - All patients who receive at least one dose of MEDI4376/placebo will be included in the safety analysis. Descriptive summary tables will be presented on safety parameters by treatment arm. There will be safety monitoring by the NCIC CTG Data Safety Monitoring Committee (DSMC) every 6 months
Timepoint [5] 0 0
every 6 months
Secondary outcome [6] 0 0
Evaluate the Quality of life between the two treatment arms in PD-L1+ patients and in all randomized patients. - The quality of life (QoL) of patients will be assessed using EORTC QLQ-C30 and the lung cancer module (QLQ-LC13) incorporated.
Timepoint [6] 0 0
5.5 years
Secondary outcome [7] 0 0
Determine survival benefits participants judge necessary to make adjuvant immunotherapy worthwhile
Timepoint [7] 0 0
5.5 years
Secondary outcome [8] 0 0
Determine the incremental cost effectiveness and cost utility ratios for MEDI4736
Timepoint [8] 0 0
5.5 years
Secondary outcome [9] 0 0
Evaluate the predictive/prognostic significance of PD-L1 expression
Timepoint [9] 0 0
5.5 years
Secondary outcome [10] 0 0
Evaluation of changes in plasma/serum cytokines and other blood and tissue based biomarkers after treatment with MEDI4736 and at disease event
Timepoint [10] 0 0
5.5 years
Secondary outcome [11] 0 0
Explore polymorphisms that may be associated with outcomes
Timepoint [11] 0 0
Baseline only

Eligibility
Key inclusion criteria
- Histologically confirmed diagnosis of primary non-small cell carcinoma of the lung.
according to WHO Classification of Tumours (WHO Classification of Tumours of the Lung,
Pleura, Thymus and Heart. WHO/IARC Classification of Tumours, 4th Edition, Volume 7).
Patients with large-cell neuroendocrine carcinomas are not eligible.

- Patients must be classified post-operatively as Stage IB (= 4cm in the longest
diameter), II or IIIA on the basis of pathologic criteria. Note: Although T3N2M0
tumours have been reclassified to stage IIIB in the 8th edition of the IASLC staging
system, these patients remain eligible (as stage IIIA under the 7th edition criteria).

- Complete surgical resection of the primary NSCLC is also mandatory. All gross
disease must have been removed at the end of surgery. All surgical margins of
resection must be negative for tumour. Resection may be accomplished by open or
VATS techniques

Note: Patients with synchronous primary tumours will not be eligible due to the potential
uncertainty regarding their appropriate PD-L1 status.

Prior Systemic Therapy:

- Pre-operative (neo-adjuvant) platinum based or other chemotherapy is not permissible.

- Patients may have received prior post-operative platinum based chemotherapy as per
standard of care.

- No prior anticancer therapy for treatment of NSCLC other than standard post-operative
adjuvant chemotherapy is permissible.

Radiation:

• Pre-operative or post-operative or planned radiation therapy is not permissible.

- The patient must have an ECOG performance status of 0, 1.

- Hematology: . Absolute neutrophil count = 1.5 x 109/L or = 1,500/µl Platelets = 100 x
109/L or = 100,000/µl

- Biochemistry:

Total bilirubin* = institutional upper limit of normal Alkaline phosphatase = 2.5 x
institutional upper limit of normal AST(SGOT) and ALT(SGPT) = 2.5 x institutional upper
limit of normal Creatinine Clearance = 40 ml/min

* excluding Gilbert's syndrome

Creatinine clearance to be measured directly by 24 hour urine sampling or as calculated by
Cockcroft Formula:

Females: GFR = 1.04 x (140-age) x weight in kg serum creatinine in µmol/L Males: GFR = 1.23
x (140-age) x weight in kg serum creatinine in µmol/L

- Patient able and willing to complete the QoL, economics and other questionnaires. The
baseline assessment must already have been completed within required timelines prior
to randomization. Inability (illiteracy, loss of sight, or other equivalent reason) to
complete the questionnaires will not make the patient ineligible for the study.
However, ability but unwillingness to complete the questionnaires will make the
patient ineligible

- Patient consent must be appropriately obtained in accordance with applicable local and
regulatory requirements. Each patient must sign a consent form prior to enrollment in
the trial to document their willingness to participate

- Patients must be accessible for treatment and follow-up. Investigators must assure
themselves the patients randomized on this trial will be available for complete
documentation of the treatment, adverse events, and follow-up

- Protocol treatment is to begin within 2 working days of patient randomization
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patients with a history of other malignancies, except:

- adequately treated non-melanoma skin cancer,

- curatively treated in-situ cancer, or

- other malignancies curatively treated with no evidence of disease for = 5 years
following the end of treatment and which, in the opinion of the treating
physician, do not have a substantial risk of recurrence of the prior malignancy.

- A combination of small cell and non-small cell lung cancer, pulmonary carcinoid tumour
or large-cell neuroendocrine carcinoma (LCNEC).

- History of autoimmune disease, including but not limited to myasthenia gravis,
myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,
inflammatory bowel disease, vascular thrombosis associated with antiphospholipid
syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome,
multiple sclerosis, vasculitis, or glomerulonephritis. NOTE: patients with Grave's
disease and/or psoriasis not requiring systemic therapy within the last two years from
randomization and patients with hypothyroidism (e.g. following Hashimoto syndrome)
stable on hormone replacement are not excluded.

- History of primary immunodeficiency, history of allogenic organ transplant that
requires therapeutic immunosuppression and the use of immunosuppressive agents within
28 days of randomization* or a prior history of severe (grade 3 or 4) immune mediated
toxicity from other immune therapy.

- Live attenuated vaccination administered within 30 days prior to randomization.

- History of hypersensitivity to MEDI4736 or any excipient.

- Patients who have experienced untreated and/or uncontrolled cardiovascular conditions
and/or have symptomatic cardiac dysfunction (unstable angina, congestive heart
failure, myocardial infarction within the previous year or cardiac ventricular
arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular
conduction defects). Patients with a significant cardiac history, even if controlled,
must have a LVEF > 50% within 12 weeks prior to randomization.

- Concurrent treatment with other investigational drugs or anti-cancer therapy.

- Patients with active or uncontrolled infections or with serious illnesses or medical
conditions which would not permit the patient to be managed according to the protocol.
This includes but is not limited to:

- known clinical diagnosis of tuberculosis;

- known active hepatitis B infection (positive HBV surface antigen (HBsAg)).
Patients with a past or resolved hepatitis B infection (defined as presence of
hepatitis B core antibody (anti-HBc) and absence of HBSAg) are eligible;

- known active hepatitis C infection. Patients positive for hepatitis C (HCV)
antibody are eligible only if polymerase chain reaction is negative for HCV RA;

- known human immunodeficiency virus infection (positive HIV antibodies).

- known pneumonitis or pulmonary fibrosis with clinically significant impairment of
pulmonary function

- Pregnant or lactating women. Women of childbearing potential must have a urine
pregnancy test proven negative within 14 days prior to randomization. Men and women of
child-bearing potential must agree to use adequate contraception.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Current
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,South, QLDTAS,VIC,WA
Recruitment hospital [1] 0 0
Campbelltown Hospital - Campbelltown
Recruitment hospital [2] 0 0
Chris O'Brien Lifehouse - Camperdown
Recruitment hospital [3] 0 0
Coffs Habour Health Campus - NCCI - Coffs Harbour
Recruitment hospital [4] 0 0
Gosford Hospital - Gosford
Recruitment hospital [5] 0 0
Nepean Hospital - Kingswood
Recruitment hospital [6] 0 0
St. George Hospital, Cancer Care Centre - Kogarah
Recruitment hospital [7] 0 0
Liverpool Cancer Therapy Centre, Liverpool Hospital - Liverpool
Recruitment hospital [8] 0 0
Northern Cancer Institute St Leonards - St Leonards
Recruitment hospital [9] 0 0
Westmead Hospital - Westmead
Recruitment hospital [10] 0 0
Princess Alexandra Hospital - Brisbane
Recruitment hospital [11] 0 0
The Prince Charles Hospital - Chermside
Recruitment hospital [12] 0 0
Nambour General Hospital - Nambour
Recruitment hospital [13] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [14] 0 0
Mater Medical Centre - Brisbane
Recruitment hospital [15] 0 0
Royal Hobart Hospital - Hobart
Recruitment hospital [16] 0 0
Monash Medical Centre - Clayton
Recruitment hospital [17] 0 0
St. Vincent's Hospital - Fitzroy
Recruitment hospital [18] 0 0
Frankston Hospital - Peninsula Oncology Centre - Frankston
Recruitment hospital [19] 0 0
Austin Hospital - Heidelberg
Recruitment hospital [20] 0 0
Royal Melbourne Hospital Research Foundation - Parkville
Recruitment hospital [21] 0 0
Epworth HealthCare - Richmond - Richmond
Recruitment hospital [22] 0 0
Border Medical Oncology - Wodonga
Recruitment hospital [23] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment hospital [24] 0 0
Sir Charles Gairdner Hospital - Perth
Recruitment hospital [25] 0 0
Flinders Medical Center - Adelaide
Recruitment hospital [26] 0 0
Canberra Hospital - Garran
Recruitment postcode(s) [1] 0 0
2560 - Campbelltown
Recruitment postcode(s) [2] 0 0
2050 - Camperdown
Recruitment postcode(s) [3] 0 0
2450 - Coffs Harbour
Recruitment postcode(s) [4] 0 0
2250 - Gosford
Recruitment postcode(s) [5] 0 0
2751 - Kingswood
Recruitment postcode(s) [6] 0 0
2217 - Kogarah
Recruitment postcode(s) [7] 0 0
2170 - Liverpool
Recruitment postcode(s) [8] 0 0
2065 - St Leonards
Recruitment postcode(s) [9] 0 0
2145 - Westmead
Recruitment postcode(s) [10] 0 0
4102 - Brisbane
Recruitment postcode(s) [11] 0 0
4032 - Chermside
Recruitment postcode(s) [12] 0 0
4560 - Nambour
Recruitment postcode(s) [13] 0 0
5000 - Adelaide
Recruitment postcode(s) [14] 0 0
4101 - Brisbane
Recruitment postcode(s) [15] 0 0
7000 - Hobart
Recruitment postcode(s) [16] 0 0
3168 - Clayton
Recruitment postcode(s) [17] 0 0
3065 - Fitzroy
Recruitment postcode(s) [18] 0 0
3199 - Frankston
Recruitment postcode(s) [19] 0 0
3084 - Heidelberg
Recruitment postcode(s) [20] 0 0
3050 - Parkville
Recruitment postcode(s) [21] 0 0
3121 - Richmond
Recruitment postcode(s) [22] 0 0
3690 - Wodonga
Recruitment postcode(s) [23] 0 0
6150 - Murdoch
Recruitment postcode(s) [24] 0 0
6009 - Perth
Recruitment postcode(s) [25] 0 0
5042 - Adelaide
Recruitment postcode(s) [26] 0 0
ACT 2605 - Garran
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
North Carolina
Country [6] 0 0
United States of America
State/province [6] 0 0
Pennsylvania
Country [7] 0 0
Canada
State/province [7] 0 0
Alberta
Country [8] 0 0
Canada
State/province [8] 0 0
British Columbia
Country [9] 0 0
Canada
State/province [9] 0 0
Manitoba
Country [10] 0 0
Canada
State/province [10] 0 0
New Brunswick
Country [11] 0 0
Canada
State/province [11] 0 0
Newfoundland and Labrador
Country [12] 0 0
Canada
State/province [12] 0 0
Nova Scotia
Country [13] 0 0
Canada
State/province [13] 0 0
Ontario
Country [14] 0 0
Canada
State/province [14] 0 0
Prince Edward Island
Country [15] 0 0
Canada
State/province [15] 0 0
Quebec
Country [16] 0 0
Canada
State/province [16] 0 0
Saskatchewan
Country [17] 0 0
France
State/province [17] 0 0
BP
Country [18] 0 0
France
State/province [18] 0 0
Cedex 04
Country [19] 0 0
France
State/province [19] 0 0
Cedex 05
Country [20] 0 0
France
State/province [20] 0 0
Cedex 20
Country [21] 0 0
France
State/province [21] 0 0
Cedex 9
Country [22] 0 0
France
State/province [22] 0 0
Cedex
Country [23] 0 0
France
State/province [23] 0 0
Angers
Country [24] 0 0
France
State/province [24] 0 0
Avignon
Country [25] 0 0
France
State/province [25] 0 0
Besancon Cedex
Country [26] 0 0
France
State/province [26] 0 0
Bobigny
Country [27] 0 0
France
State/province [27] 0 0
Bordeaux
Country [28] 0 0
France
State/province [28] 0 0
Boulogne
Country [29] 0 0
France
State/province [29] 0 0
Bron
Country [30] 0 0
France
State/province [30] 0 0
Caen
Country [31] 0 0
France
State/province [31] 0 0
Chalon-sur-saone
Country [32] 0 0
France
State/province [32] 0 0
Cholet
Country [33] 0 0
France
State/province [33] 0 0
Clamart
Country [34] 0 0
France
State/province [34] 0 0
Clermont-Ferrand
Country [35] 0 0
France
State/province [35] 0 0
Colmar
Country [36] 0 0
France
State/province [36] 0 0
Contamine Sur Arve
Country [37] 0 0
France
State/province [37] 0 0
Creteil
Country [38] 0 0
France
State/province [38] 0 0
Dijon
Country [39] 0 0
France
State/province [39] 0 0
Elbeuf
Country [40] 0 0
France
State/province [40] 0 0
La Roche Sur Yon
Country [41] 0 0
France
State/province [41] 0 0
Le Chesnay
Country [42] 0 0
France
State/province [42] 0 0
Le Mans
Country [43] 0 0
France
State/province [43] 0 0
Lille
Country [44] 0 0
France
State/province [44] 0 0
Lyon
Country [45] 0 0
France
State/province [45] 0 0
Macon
Country [46] 0 0
France
State/province [46] 0 0
Marseille
Country [47] 0 0
France
State/province [47] 0 0
Meaux
Country [48] 0 0
France
State/province [48] 0 0
Metz-Tessy
Country [49] 0 0
France
State/province [49] 0 0
Mulhouse
Country [50] 0 0
France
State/province [50] 0 0
Nice
Country [51] 0 0
France
State/province [51] 0 0
Orleans
Country [52] 0 0
France
State/province [52] 0 0
Paris
Country [53] 0 0
France
State/province [53] 0 0
Pau
Country [54] 0 0
France
State/province [54] 0 0
Perigueux
Country [55] 0 0
France
State/province [55] 0 0
Pontoise
Country [56] 0 0
France
State/province [56] 0 0
Rouen
Country [57] 0 0
France
State/province [57] 0 0
Saint-Brieuc
Country [58] 0 0
France
State/province [58] 0 0
Saint-priest-en-jarez
Country [59] 0 0
France
State/province [59] 0 0
Saint-Quentin
Country [60] 0 0
France
State/province [60] 0 0
Strasbourg
Country [61] 0 0
France
State/province [61] 0 0
Suresnes
Country [62] 0 0
France
State/province [62] 0 0
Thonon Les Bains
Country [63] 0 0
France
State/province [63] 0 0
Toulon
Country [64] 0 0
France
State/province [64] 0 0
Toulouse
Country [65] 0 0
France
State/province [65] 0 0
Villefranche Sur Saone
Country [66] 0 0
Hungary
State/province [66] 0 0
Budapest
Country [67] 0 0
Italy
State/province [67] 0 0
AN
Country [68] 0 0
Italy
State/province [68] 0 0
AV
Country [69] 0 0
Italy
State/province [69] 0 0
BA
Country [70] 0 0
Italy
State/province [70] 0 0
GE
Country [71] 0 0
Italy
State/province [71] 0 0
Lombardia
Country [72] 0 0
Italy
State/province [72] 0 0
PG
Country [73] 0 0
Italy
State/province [73] 0 0
PN
Country [74] 0 0
Italy
State/province [74] 0 0
PV
Country [75] 0 0
Italy
State/province [75] 0 0
RA
Country [76] 0 0
Italy
State/province [76] 0 0
RM
Country [77] 0 0
Italy
State/province [77] 0 0
VA
Country [78] 0 0
Italy
State/province [78] 0 0
VR
Country [79] 0 0
Italy
State/province [79] 0 0
Benevento
Country [80] 0 0
Italy
State/province [80] 0 0
Brindisi
Country [81] 0 0
Italy
State/province [81] 0 0
Catania
Country [82] 0 0
Italy
State/province [82] 0 0
Meldola
Country [83] 0 0
Italy
State/province [83] 0 0
Milan
Country [84] 0 0
Italy
State/province [84] 0 0
Mirano
Country [85] 0 0
Italy
State/province [85] 0 0
Napoli
Country [86] 0 0
Italy
State/province [86] 0 0
Padova
Country [87] 0 0
Italy
State/province [87] 0 0
Piacenza
Country [88] 0 0
Italy
State/province [88] 0 0
Rome
Country [89] 0 0
Japan
State/province [89] 0 0
Aichi
Country [90] 0 0
Japan
State/province [90] 0 0
Chiba
Country [91] 0 0
Japan
State/province [91] 0 0
Ehime
Country [92] 0 0
Japan
State/province [92] 0 0
Fukuoka
Country [93] 0 0
Japan
State/province [93] 0 0
Gunma
Country [94] 0 0
Japan
State/province [94] 0 0
Hiroshima
Country [95] 0 0
Japan
State/province [95] 0 0
Ishikawa
Country [96] 0 0
Japan
State/province [96] 0 0
Miyagi
Country [97] 0 0
Japan
State/province [97] 0 0
Okayama
Country [98] 0 0
Japan
State/province [98] 0 0
Osaka
Country [99] 0 0
Japan
State/province [99] 0 0
Yamaguchi
Country [100] 0 0
Japan
State/province [100] 0 0
Tokyo
Country [101] 0 0
Japan
State/province [101] 0 0
Yokohama City
Country [102] 0 0
Korea, Republic of
State/province [102] 0 0
Chungcheongbuk do
Country [103] 0 0
Korea, Republic of
State/province [103] 0 0
Dongjak gu
Country [104] 0 0
Korea, Republic of
State/province [104] 0 0
Gangdong-gu
Country [105] 0 0
Korea, Republic of
State/province [105] 0 0
Gyeonggi do
Country [106] 0 0
Korea, Republic of
State/province [106] 0 0
Jung Gu
Country [107] 0 0
Korea, Republic of
State/province [107] 0 0
Seoul
Country [108] 0 0
Netherlands
State/province [108] 0 0
Gelderland
Country [109] 0 0
Netherlands
State/province [109] 0 0
Noord Brabant
Country [110] 0 0
Netherlands
State/province [110] 0 0
Noord Holland
Country [111] 0 0
Netherlands
State/province [111] 0 0
Overijssel
Country [112] 0 0
Netherlands
State/province [112] 0 0
Amsterdam
Country [113] 0 0
Netherlands
State/province [113] 0 0
Groningen
Country [114] 0 0
Netherlands
State/province [114] 0 0
Maastricht
Country [115] 0 0
Netherlands
State/province [115] 0 0
Rotterdam
Country [116] 0 0
New Zealand
State/province [116] 0 0
Christchurch
Country [117] 0 0
Singapore
State/province [117] 0 0
Singapore
Country [118] 0 0
Spain
State/province [118] 0 0
Barcelona
Country [119] 0 0
Spain
State/province [119] 0 0
Gran Canaria
Country [120] 0 0
Spain
State/province [120] 0 0
Alicante
Country [121] 0 0
Spain
State/province [121] 0 0
Coruna
Country [122] 0 0
Spain
State/province [122] 0 0
Leon
Country [123] 0 0
Spain
State/province [123] 0 0
Madrid
Country [124] 0 0
Spain
State/province [124] 0 0
Palma de Mallorca
Country [125] 0 0
Spain
State/province [125] 0 0
Salamanca
Country [126] 0 0
Spain
State/province [126] 0 0
Valencia
Country [127] 0 0
Taiwan
State/province [127] 0 0
Taiwan;
Country [128] 0 0
Taiwan
State/province [128] 0 0
Chiayi City
Country [129] 0 0
Taiwan
State/province [129] 0 0
Hualien
Country [130] 0 0
Taiwan
State/province [130] 0 0
Kaohsiung City
Country [131] 0 0
Taiwan
State/province [131] 0 0
Kaohsiung
Country [132] 0 0
Taiwan
State/province [132] 0 0
New Taipei City
Country [133] 0 0
Taiwan
State/province [133] 0 0
Taichung
Country [134] 0 0
Taiwan
State/province [134] 0 0
Taipei
Country [135] 0 0
Taiwan
State/province [135] 0 0
Taoyuan City

Funding & Sponsors
Primary sponsor type
Other
Name
Canadian Cancer Trials Group
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Intergroupe Francophone de Cancerologie Thoracique (IFCT)
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Australasian Lung Cancer Trials Group
Address [2] 0 0
Country [2] 0 0
Other collaborator category [3] 0 0
Other
Name [3] 0 0
National Health and Medical Research Council, Australia
Address [3] 0 0
Country [3] 0 0
Other collaborator category [4] 0 0
Other
Name [4] 0 0
National Cancer Institute (NCI), Naples
Address [4] 0 0
Country [4] 0 0
Other collaborator category [5] 0 0
Other
Name [5] 0 0
Central and Eastern European Oncology Group
Address [5] 0 0
Country [5] 0 0
Other collaborator category [6] 0 0
Other
Name [6] 0 0
Dutch Society of Physicians for Pulmonology and Tuberculosis
Address [6] 0 0
Country [6] 0 0
Other collaborator category [7] 0 0
Other
Name [7] 0 0
Korean Cancer Study Group
Address [7] 0 0
Country [7] 0 0
Other collaborator category [8] 0 0
Other
Name [8] 0 0
Spanish Lung Cancer Group
Address [8] 0 0
Country [8] 0 0
Other collaborator category [9] 0 0
Other
Name [9] 0 0
West Japan Oncology Group (WJOG)
Address [9] 0 0
Country [9] 0 0
Other collaborator category [10] 0 0
Other
Name [10] 0 0
Chinese Thoracic Oncology Group
Address [10] 0 0
Country [10] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to find out whether it is better to receive a new drug,
MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy)
for lung cancer.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Glenwood Goss
Address 0 0
Ottawa Hospital Research Institute, Ontario, Canada
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Chris O'Callaghan
Address 0 0
Country 0 0
Phone 0 0
613-533-6430
Fax 0 0
Email 0 0
cocallaghan@ctg.queensu.ca
Contact person for scientific queries
Contact person responsible for updating information